Psychopharmacology
Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects.
Yana Babii, Agnieszka Pałucha-Poniewiera, Bartosz Bobula, Agnieszka Kania, Dorota Bederska-Łojewska, Piotr Brański, Andrzej Pilc
Published: 202510.1007/s00213-025-06916-6
Abstract
RATIONALE: Scopolamine, whose rapid and sustained antidepressant effects were first described nearly two decades ago, is associated with significant adverse effects that limit its clinical use. A safer alternative may involve coadministration of scop…
Preview only. Read the full abstract at the source